AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35250344 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooling trial (ice-cold towels on forehead and neck for 3 min during offensive half innings)
Number of subjects: 10
Study 35250344 — intervention group
Group type: COMPARATOR
Intervention: Control trial (no cooling intervention)
Number of subjects: 10
Study 35250344 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooling trial
Number of subjects: 10
Study 35250344 — intervention group
Group type: COMPARATOR
Intervention: Cooling trial and Control trial
Number of subjects: 10
Study 32006699 — intervention group
Group type: EXPERIMENTAL
Intervention: Levorphanol (potent opioid), average final daily dose 132 mg (range 14 to 300 mg), with 5 weeks titration followed by 20 weeks stable dosing.
Number of subjects: 30
Study 34018365 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperin treatment at 75 mg/(kg·d) for 4 weeks
Number of subjects: 120
Study 34018365 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 120
Study 34018365 — intervention group
Group type: COMPARATOR
Intervention: POI model group (TG at 40 mg/kg twice a day for 2 weeks)
Number of subjects: 120
Study 34914418 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Stress Management (CBSM) intervention (n = 55)
Number of subjects: 100
Study 34914418 — intervention group
Group type: COMPARATOR
Intervention: Attentional control condition (n = 45)
Number of subjects: 100
Study 34177646 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi training (3 sessions of 60 minutes per week for 12 weeks)
Number of subjects: 76
Study 32777010 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated amyloid levels
Number of subjects: 1705
Study 32777010 — intervention group
Group type: COMPARATOR
Intervention: Not elevated amyloid levels
Number of subjects: 1705
Study 36164417 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality Control Circle Activity Care (QCCAC)
Number of subjects: 119
Study 33709808 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived discrimination due to race
Number of subjects: 0
Study 35988261 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft-voting classifier using SVM, LR, and KNN
Number of subjects: 101
Study 35988261 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning classification models (RF, XGBoost, SVM, LR, KNN)
Number of subjects: 101
Study 32434666 — intervention group
Group type: EXPERIMENTAL
Intervention: HeatTens (n=25)
Number of subjects: 50
Study 32434666 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=25)
Number of subjects: 50
Study 32714989 — intervention group
Group type: EXPERIMENTAL
Intervention: Jaques-Dalcroze Eurhythmics exercise programme (12 weeks, twice a week for 45 minutes)
Number of subjects: 73
Study 32714989 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 73
Study 32714989 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (IG and CG)
Number of subjects: 73
Study 35476094 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiprofessional remote intervention with a nurse for 16 weeks via a messaging application
Number of subjects: 0
Study 33252564 — intervention group
Group type: COMPARATOR
Intervention: Ophthalmic Viscosurgical Device (OVD)
Number of subjects: 100
Study 33252564 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior Chamber Maintainer (ACM)
Number of subjects: 100
Study 33252564 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (OVD and ACM)
Number of subjects: 100
Study 35314199 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vitamin D3 (10,000 IU daily for 5 or 14 days) prior to debridement and PDT
Number of subjects: 58
Study 35314199 — intervention group
Group type: COMPARATOR
Intervention: Standard PDT regimen without vitamin D3 pretreatment
Number of subjects: 58
Study 35314199 — intervention group
Group type: COMPARATOR
Intervention: Patients with VD3 deficiency (< 31 ng/dL) in group 1
Number of subjects: 58
Study 35314199 — intervention group
Group type: COMPARATOR
Intervention: Patients with normal 25-hydroxyvitamin D3 levels in group 1
Number of subjects: 58
Study 33441705 — intervention group
Group type: EXPERIMENTAL
Intervention: I1 (50% of crop's water requirement)
Number of subjects: 12
Study 33441705 — intervention group
Group type: EXPERIMENTAL
Intervention: I2 (75% of crop's water requirement)
Number of subjects: 12
Study 33441705 — intervention group
Group type: COMPARATOR
Intervention: I3 (100% of crop's water requirement, non-stress treatment)
Number of subjects: 12
Study 33441705 — intervention group
Group type: EXPERIMENTAL
Intervention: I4 (125% of crop's water requirement)
Number of subjects: 12
Study 35122594 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine Position (SP)
Number of subjects: 224
Study 35122594 — intervention group
Group type: EXPERIMENTAL
Intervention: Left Lateral Position (LLP)
Number of subjects: 224
Study 35122594 — intervention group
Group type: EXPERIMENTAL
Intervention: Left Lateral Position (LLP) in patients with BMI < 21 kg/m2
Number of subjects: 224
Study 35122594 — intervention group
Group type: EXPERIMENTAL
Intervention: Left Lateral Position (LLP) in patients who underwent gastrectomy within three years
Number of subjects: 224
Study 35122594 — intervention group
Group type: COMPARATOR
Intervention: Starting position (SP or LLP)
Number of subjects: 224
Study 34565137 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotype-specific regimens
Number of subjects: 795
Study 34565137 — intervention group
Group type: COMPARATOR
Intervention: Pangenotypic regimens
Number of subjects: 795
Study 35917364 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose albendazole
Number of subjects: 5759
Study 35917364 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose mebendazole
Number of subjects: 5759
Study 35917364 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5759
Study 35513980 — intervention group
Group type: EXPERIMENTAL
Intervention: Loncastuximab tesirine (Lonca)
Number of subjects: 80
Study 35513980 — intervention group
Group type: COMPARATOR
Intervention: Chemoimmunotherapy (CIT)
Number of subjects: 80
Study 35595817 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential paclitaxel treatment followed by fluorinated‐pyrimidine‐based adjuvant chemotherapy
Number of subjects: 556
Study 35595817 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy (not explicitly named in the abstract)
Number of subjects: 556
Study 32227432 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 or 25 mg
Number of subjects: 7020
Study 32227432 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7020
Study 35637324 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescription-grade Crystalline Glucosamine Sulfate (pCGS) 1500 mg/day
Number of subjects: 123
Study 35637324 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy alone
Number of subjects: 123
Study 34218304 — intervention group
Group type: EXPERIMENTAL
Intervention: Rupatadine (RUP) 10 mg once daily
Number of subjects: 75
Study 34218304 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast (MON) 10 mg once daily
Number of subjects: 75
Study 34218304 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (MTX) 15–25 mg/week plus placebo
Number of subjects: 75
Study 32182922 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity
Number of subjects: 444
Study 32182922 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence to the Mediterranean diet
Number of subjects: 444
Study 32590411 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated flexible frame group
Number of subjects: 12
Study 32590411 — intervention group
Group type: COMPARATOR
Intervention: Krackow group
Number of subjects: 12
Study 32382528 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual exercise program designed based on six factors with ideal cutoff thresholds
Number of subjects: 0
Study 32382528 — intervention group
Group type: EXPERIMENTAL
Intervention: Cutoff values determined from the elderly human database
Number of subjects: 0
Study 32382528 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical function tests
Number of subjects: 0
Study 34675150 — intervention group
Group type: EXPERIMENTAL
Intervention: Trehalose 3%/hyaluronic acid 0.15% eyedrops (Group A)
Number of subjects: 98
Study 34675150 — intervention group
Group type: COMPARATOR
Intervention: Hyaluronic acid 0.15% eyedrops (Group B)
Number of subjects: 98
Study 34675150 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Group C)
Number of subjects: 98
Study 34234406 — intervention group
Group type: COMPARATOR
Intervention: NSAID (group C)
Number of subjects: 470
Study 34234406 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of NSAID and steroid eye drops (group A)
Number of subjects: 470
Study 34234406 — intervention group
Group type: EXPERIMENTAL
Intervention: Drop-less surgery (peri-operative subtenon depot of dexamethasone, group E)
Number of subjects: 470
Study 34234406 — intervention group
Group type: COMPARATOR
Intervention: NSAID (groups C and D)
Number of subjects: 470
Study 34234406 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of NSAID and steroid eye drops (groups A and B)
Number of subjects: 470
Study 32865057 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold sterile water (5.74 °C)
Number of subjects: 27
Study 32865057 — intervention group
Group type: EXPERIMENTAL
Intervention: Room temperature sterile water (26.89 °C)
Number of subjects: 27
Study 32865057 — intervention group
Group type: COMPARATOR
Intervention: Nothing instilled before dressing change
Number of subjects: 27
Study 35167359 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga-Based Lifestyle Intervention (YBLI)
Number of subjects: 72
Study 35167359 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 72
Study 33872339 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT)
Number of subjects: 8
Study 33872339 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 8
Study 32394663 — intervention group
Group type: EXPERIMENTAL
Intervention: Expertise-based pragmatic randomized controlled trial (EB-PRCT)
Number of subjects: 0
Study 32394663 — intervention group
Group type: COMPARATOR
Intervention: Pragmatic randomized controlled trial (PRCT)
Number of subjects: 0
Study 32394663 — intervention group
Group type: COMPARATOR
Intervention: Expertise-based randomized controlled trial (EBRCT)
Number of subjects: 0
Study 36217115 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational program explaining the importance of hospital cesarean rates and an interactive tool presenting hospital cesarean rates as 1-to-5-star ratings.
Number of subjects: 120621
Study 36217115 — intervention group
Group type: COMPARATOR
Intervention: Educational program about hospital choice and a hospital choice tool without cesarean rate data.
Number of subjects: 120621
Study 34004481 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed umbilical cord clamping (60 s after delivery)
Number of subjects: 204
Study 34004481 — intervention group
Group type: COMPARATOR
Intervention: Immediate umbilical cord clamping (0‐15 s)
Number of subjects: 204
Study 34004481 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed umbilical cord clamping
Number of subjects: 204
Study 34004481 — intervention group
Group type: COMPARATOR
Intervention: Immediate umbilical cord clamping
Number of subjects: 204
Study 34004481 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 204
Study 32485438 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrate dose
Number of subjects: 103
Study 32485438 — intervention group
Group type: EXPERIMENTAL
Intervention: Albumin
Number of subjects: 103
Study 32485438 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactate
Number of subjects: 103
Study 32485438 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrate target
Number of subjects: 103
Study 32485438 — intervention group
Group type: EXPERIMENTAL
Intervention: pH
Number of subjects: 103
Study 32485438 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphate
Number of subjects: 103
Study 32485438 — intervention group
Group type: EXPERIMENTAL
Intervention: APACHE score
Number of subjects: 103
Study 34069379 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss of Significance, Obsessive passion, Harmonious passion, Moral disengagement strategies
Number of subjects: 437
Study 32070122 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based music intervention (n=26), delivered twice weekly for 12 weeks
Number of subjects: 46
Study 32070122 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based music intervention (n=26)
Number of subjects: 46
Study 32070122 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=20)
Number of subjects: 46
Study 35046193 — intervention group
Group type: EXPERIMENTAL
Intervention: Bur
Number of subjects: 120
Study 35046193 — intervention group
Group type: EXPERIMENTAL
Intervention: OPTIDISC
Number of subjects: 120
Study 35046193 — intervention group
Group type: EXPERIMENTAL
Intervention: SUPERSNAP
Number of subjects: 120
Study 35046193 — intervention group
Group type: EXPERIMENTAL
Intervention: BISCO
Number of subjects: 120
Study 35046193 — intervention group
Group type: COMPARATOR
Intervention: Untreated group (control)
Number of subjects: 120
Study 32009610 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG-lactulose
Number of subjects: 360
Study 630982953 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2.5 mg twice daily plus aspirin 100 mg daily
Number of subjects: 27395
Study 630982953 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 5 mg twice daily alone
Number of subjects: 27395
Study 630982953 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 100 mg alone
Number of subjects: 27395
Study 630982953 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban and aspirin
Number of subjects: 27395
Study 630982953 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 27395
Study 616725657 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized Training Group (RTG; n = 50)
Number of subjects: 70
Study 616725657 — intervention group
Group type: COMPARATOR
Intervention: Periodized Group (PG; n = 11)
Number of subjects: 70
Study 35239448 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherent to PrEP
Number of subjects: 381
Study 35239448 — intervention group
Group type: COMPARATOR
Intervention: Non-adherent to PrEP
Number of subjects: 381
Study 34048281 — intervention group
Group type: EXPERIMENTAL
Intervention: Large dose of shoulder strengthening added to usual nonoperative care
Number of subjects: 200
Study 34048281 — intervention group
Group type: COMPARATOR
Intervention: Usual nonoperative care
Number of subjects: 200
Study 34138464 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone- and app-based questionnaire for caregivers to report changes in mental or physical health of clients, generating change-in-condition reports.
Number of subjects: 40137
Study 34138464 — intervention group
Group type: COMPARATOR
Intervention: Control condition with no questionnaire.
Number of subjects: 40137
Study 32475277 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized regimen based on pharmacogenetic results
Number of subjects: 31
Study 32475277 — intervention group
Group type: COMPARATOR
Intervention: Standard postoperative pain regimen (Control)
Number of subjects: 31
Study 36456417 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorsal Root Ganglion (DRG) stimulation
Number of subjects: 18
Study 36456417 — intervention group
Group type: COMPARATOR
Intervention: Conventional Medical Management (CMM)
Number of subjects: 18
Study 32041613 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined group (FICB + DEX)
Number of subjects: 119
Study 32041613 — intervention group
Group type: EXPERIMENTAL
Intervention: FICB group
Number of subjects: 119
Study 32041613 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 119
Study 34865316 — intervention group
Group type: EXPERIMENTAL
Intervention: Low surgical complexity (SCS) surgery
Number of subjects: 195
Study 34865316 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate surgical complexity (SCS) surgery
Number of subjects: 195
Study 34865316 — intervention group
Group type: EXPERIMENTAL
Intervention: High surgical complexity (SCS) surgery
Number of subjects: 195
Study 34865316 — intervention group
Group type: EXPERIMENTAL
Intervention: All surgical complexity (SCS) groups
Number of subjects: 195
Study 33284821 — intervention group
Group type: EXPERIMENTAL
Intervention: Scabies prevalence
Number of subjects: 1318
Study 33284821 — intervention group
Group type: EXPERIMENTAL
Intervention: Impetigo or infected scabies prevalence
Number of subjects: 1318
Study 33284821 — intervention group
Group type: EXPERIMENTAL
Intervention: Severity of scabies cases
Number of subjects: 1318
Study 33284821 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-related quality of life (HRQoL) impact
Number of subjects: 1318
Study 35639159 — intervention group
Group type: EXPERIMENTAL
Intervention: m-ERBT
Number of subjects: 180
Study 35639159 — intervention group
Group type: EXPERIMENTAL
Intervention: b-ERBT
Number of subjects: 180
Study 35639159 — intervention group
Group type: EXPERIMENTAL
Intervention: l-ERBT
Number of subjects: 180
Study 33530530 — intervention group
Group type: EXPERIMENTAL
Intervention: Meal replacement‐based lifestyle intervention group (INT)
Number of subjects: 119
Study 33530530 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle intervention control group (CON)
Number of subjects: 119
Study 32539815 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic stem cell transplantation (allo‐HSCT)
Number of subjects: 125
Study 32539815 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 125
Study 32539815 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic stem cell transplantation (allo‐HSCT) with c-KIT mutation
Number of subjects: 125
Study 32539815 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy with c-KIT mutation
Number of subjects: 125
Study 32539815 — intervention group
Group type: EXPERIMENTAL
Intervention: Extramedullary infiltration (EI) at diagnosis
Number of subjects: 125
Study 35475599 — intervention group
Group type: EXPERIMENTAL
Intervention: Values Exchange (Vx) online learning environment
Number of subjects: 91
Study 33843820 — intervention group
Group type: EXPERIMENTAL
Intervention: Ayahuasca
Number of subjects: 22
Study 33843820 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 35640916 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure control
Number of subjects: 778
Study 35640916 — intervention group
Group type: COMPARATOR
Intervention: Standard blood pressure control (implied control group)
Number of subjects: 778
Study 35820939 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive aids (CA) used during simulated medical emergencies
Number of subjects: 80
Study 35820939 — intervention group
Group type: COMPARATOR
Intervention: No cognitive aids (CA) used during simulated medical emergencies
Number of subjects: 80
Study 33766992 — intervention group
Group type: EXPERIMENTAL
Intervention: IV immunoglobulin (IVIG) 2 g/kg body weight followed by 3 additional infusions of 1 g/kg at 3-week intervals
Number of subjects: 60
Study 33766992 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% saline)
Number of subjects: 60
Study 33766992 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIG
Number of subjects: 60
Study 33766992 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 34817561 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I)
Number of subjects: 291
Study 34817561 — intervention group
Group type: COMPARATOR
Intervention: Sleep Education Therapy (SET)
Number of subjects: 291
Study 34817561 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I) with sustained remission of insomnia disorder
Number of subjects: 291
Study 33625893 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity monitor alone
Number of subjects: 0
Study 33625893 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity monitor plus web-based PA intervention
Number of subjects: 0
Study 33625893 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 32215847 — intervention group
Group type: EXPERIMENTAL
Intervention: Continually employed
Number of subjects: 1168
Study 32215847 — intervention group
Group type: EXPERIMENTAL
Intervention: Continual unemployment
Number of subjects: 1168
Study 32215847 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial psychological distress
Number of subjects: 1168
Study 32215847 — intervention group
Group type: EXPERIMENTAL
Intervention: Transitional employment status
Number of subjects: 1168
Study 35714359 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine and triamcinolone infiltration
Number of subjects: 128
Study 35714359 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 128
Study 33347320 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician-delivered prevention messages (3 video messages regarding COVID-19)
Number of subjects: 14267
Study 33347320 — intervention group
Group type: EXPERIMENTAL
Intervention: Messages from race/ethnicity-concordant physicians
Number of subjects: 14267
Study 35079787 — intervention group
Group type: EXPERIMENTAL
Intervention: Triventricular (TriV) pacing
Number of subjects: 99
Study 35079787 — intervention group
Group type: COMPARATOR
Intervention: Biventricular (BiV) pacing
Number of subjects: 99
Study 34556520 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24 IU, 48 IU)
Number of subjects: 0
Study 34556520 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35194158 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib therapy
Number of subjects: 1364
Study 35194158 — intervention group
Group type: EXPERIMENTAL
Intervention: IMTF model
Number of subjects: 1364
Study 33977752 — intervention group
Group type: EXPERIMENTAL
Intervention: RCA care (observation group)
Number of subjects: 94
Study 33977752 — intervention group
Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 94
Study 35285302 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fidelity simulation experience
Number of subjects: 150
Study 32366199 — intervention group
Group type: EXPERIMENTAL
Intervention: Social and financial barriers to receiving health care
Number of subjects: 393430
Study 32366199 — intervention group
Group type: EXPERIMENTAL
Intervention: Race/Ethnicity
Number of subjects: 393430